Angiogenic Activity of Sera from Pulmonary Tuberculosis Patients in Relation to IL-12p40 and TNFα Serum Levels

Tadeusz M. Zielonka · Urszula Demkow · Dorota Michalowska-Mitczuk · Malgorzata Filewska · Beata Bialas · Katarzyna Zycinska · Michael H. Obrowski · Jan Kus · Ewa Skopinska-Rozewska

Received: 2 February 2010 / Accepted: 3 April 2011 / Published online: 21 May 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract The role of angiogenesis in the pathogenesis of tuberculosis (TB) is not clear. The aim of this study was to examine the effect of sera from TB patients on angiogenesis induced by different subsets of normal human mononuclear cells (MNC) in relation to IL-12p40 and TNFα serum levels. Serum samples from 36 pulmonary TB patients and from 22 healthy volunteers were evaluated. To assess angiogenic reaction the leukocytes-induced angiogenesis test according to Sidky and Auerbach was performed. IL-12p40 and TNFα serum levels were evaluated by ELISA. Sera from TB patients significantly stimulated angiogenic activity of MNC compared to sera from healthy donors and PBS (p < 0.001). The number of microvessels formed after injection of lymphocytes preincubated with sera from TB patients was significantly lower compared to the number of microvessels created after injection of MNC preincubated with the same sera (p < 0.016). However, the number of microvessels created after the injection of lymphocytes preincubated with sera from healthy donors or with PBS alone was significantly higher (p < 0.017). The mean levels of IL-12p40 and TNFα were significantly elevated in sera from TB patients compared to healthy donors. We observed a correlation between angiogenic activity of sera from TB patients and IL-12p40 and TNFα serum levels (p < 0.01). Sera from TB patients constitute a source of mediators that participate in angiogenesis and prime monocytes for production of proangiogenic factors. The main proangiogenic effect of TB patients’ sera is mediated by macrophages/monocytes. TNFα and IL-12p40 may indirectly stimulate angiogenesis in TB.

Keywords Angiogenesis · Tuberculosis · Pathogenesis · Interleukin-12p40 · Tumor necrosis factor alpha

Introduction

Angiogenesis from preexisting vasculature occurs in many pathological conditions such as tumors [1], cardiovascular diseases [2], chronic inflammation [2, 3], rheumatoid arthritis [4], diabetic retinopathy [5], endometriosis [6], and obesity [7]. In pulmonary nonmalignant diseases angiogenesis has been implicated in the pathogenesis of idiopathic interstitial pneumonia [8], lung fibrosis induced by bleomycin [9], and sarcoidosis [10]. Vascular endothelial growth factor (VEGF) is a fundamental regulator of normal and pathological angiogenesis [11]. Ischemia induces both VEGF production and angiogenesis [12]. Although there have been reports concerning angiogenesis in infectious diseases, its role in the pathogenesis of TB has not been determined [13, 14]. Serum VEGF might be a useful marker as a prognostic indicator in sarcoidosis [15] and other granulomatous diseases, including TB. Increased VEGF levels in serum [16–18], pleural fluid [19, 20] and cerebrospinal fluid [21] have been found in
patients with active TB. VEGF therefore may be associated with the pathogenesis of pulmonary TB in the development of the chronic inflammatory reaction [18]. M. tuberculosis antigens are considered an important factor participating in the pathogenesis of Eales’ disease—an idiopathic retinal periphlebitis characterized by capillary nonperfusion and angiogenesis [22]. In one study, an intense angiogenesis was shown ultrastructurally in active pulmonary tuberculosis lesions [23], but the meaning of this phenomenon is not completely understood yet. An important role in the pathogenesis of TB and also in the modulation of angiogenesis is played by some cytokines, especially IL-12 and TNF-α [24–26]. The aim of this study was to examine the effect of sera from TB patients on angiogenesis induced by different subsets of normal human mononuclear cells (MNC) in relation to IL-12p40 and TNF-α serum levels.

Materials and Methods

Study Population

The study was approved by the local ethics committee. Serum samples were obtained from 36 patients with active pulmonary TB and from 22 healthy volunteers. The TB group consisted of 26 male and 10 female patients aged 49.8 ± 14.9 years (range = 23–75 years). All were HIV-negative and 23 were smokers. The diagnosis of pulmonary TB was confirmed by a conventional sputum culture. No systemic or extrapulmonary TB was observed. Blood samples were taken from patients before antituberculosis treatment was started. As a control, sera from 22 healthy nonsmoking volunteers were used (12 women and 10 men, mean age = 38.7 ± 11.4, range = 20-58 years). None of the control volunteers had any past medical history of tuberculosis, other pulmonary diseases, or cancer.

Preparation of Peripheral Blood Mononuclear Cells

Blood from healthy donors attending the Warsaw Central Blood Bank was collected in a heparinized syringe, then diluted 1:1 in phosphate-buffered saline (PBS) and layered over Lymphoprep separation medium (Sigma). After spinning the tubes for 20 min at 500 g, the mononuclear fraction was aspirated from the interface. MNC viability estimated by trypan blue stain was ≥ 98%. This method yielded MNC preparation containing 10-15% monocytes and 85-90% lymphocytes based on morphologic criteria and myeloperoxidase staining. MNC were depleted of monocytes by glass adherence and phagocytosis of iron particles using 15 mg for 10 × 10⁶ cells.

Leukocyte-induced Angiogenesis Assay (LIA)

To assess the effect of sera from TB patients on angiogenesis induced by different fractions of MNC, a leukocyte-induced angiogenesis test described by Sidky and Auerbach in an animal model [27] with modification [10, 28] was used. The local ethical commission for experimenting on animals approved all procedures involved in this study. Female inbred 8-week-old BALB/c mice served as recipients of MNC or lymphocytes preincubated in PBS supplemented with 25% of serum from TB patients or from healthy volunteers for 1 h at 37°C. As a control, other mice were given MNC or lymphocytes that were preincubated only in PBS. Mice were anesthetized with 3.6% chloral hydrate (POCH, Poland) and injected intradermally with 5 × 10⁵ cells in Parker liquid (6 injections per mice and 3 mice for each tested patient). The mice were killed after 3 days. The newly formed blood vessels were identified and counted on the inner surface of the skin of each mouse using a microscope (Nikon, Japan) at 6 × magnification. In all cases identification was performed by one expert (UD) based on the previously described criteria [27].

Cytokines

IL-12p40 and TNF-α in sera were evaluated by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (BIOSOURCE Europe S.A.) according to the manufacturer’s instructions. Recombinant TNF-α (NIBSC, Hertfordshire, UK, EN6 3 QG) was used as a standard. Concentrations of IL-12p40 in sera were determined by sandwich ELISA using specific IL-12p40 MoAb. Optical density was measured at 450 nm using spectrophotometric reader Elx800 (Biotek Instruments, Inc., USA).

Statistical Analysis

The value of the angiogenesis test was expressed as an angiogenesis index (AI):

\[
AI = A_{ex}/A_{contr}
\]

where \(A_{ex}\) is the mean number of micro blood vessels created after the injection of MNC or lymphocytes preincubated in PBS with the serum of a patient or healthy donor, and \(A_{contr}\) is the mean number of micro blood vessels created after the injection of MNC or lymphocytes preincubated with PBS alone.

All results are presented as mean ± SD. Statistical evaluation of the results was performed using Pearson’s test, Student’s \(t\)-test, and Mann-Whitney test (Statistica 6 for Windows, Statsoft, Tulsa, OK, USA). A \(p\) value < 0.05 was used to indicate statistical significance.
Results

Angiogenic activity of MNC was measured by the mean number of newly formed vessels after injection of MNC preincubated with sera and PBS or with PBS alone. Sera from TB patients significantly indirectly stimulated angiogenesis to a greater extent than sera from healthy donors or PBS alone ($p < 0.001$) (Fig. 1). Proangiogenic activity of sera from TB patients (mean number of microvessels = 16.9 $\pm$ 0.9) was significantly higher than that of sera from healthy donors (13.99 $\pm$ 0.73 vessels; $p < 0.001$). However, sera from healthy donors also significantly ($p < 0.001$) stimulated angiogenic activity of normal MNC compared to MNC preincubated only with PBS (12.7 $\pm$ 1.16 vessels).

Following the injection of lymphocytes preincubated with sera from 20 TB patients, the mean number of microvessels significantly decreased (16 $\pm$ 1.33; $p < 0.05$) compared to the number of microvessels after the injection of a full suspension of MNC preincubated with the same sera (17 $\pm$ 0.79) (Fig. 2a). However, the mean number of microvessels after injection of lymphocytes preincubated with sera from healthy donors significantly increased (from 13.99 $\pm$ 0.73 to 14.8 $\pm$ 1.0; $p < 0.01$) compared to the number of microvessels after the injection of a full suspension of MNC preincubated with the same sera (Fig. 2b). A similar effect was observed in the control group when MNC or lymphocytes were preincubated with PBS alone (increase from 12.7 $\pm$ 1.16 to 13.8 $\pm$ 1.63; $p < 0.05$) (Fig. 2c). The results were expressed as an angiogenic index and the following relationships were observed: After injection of MNC preincubated with sera from TB patients, AI was 1.29 $\pm$ 0.03 but it significantly decreased (1.12 $\pm$ 0.09; $p < 0.001$) following preincubation of lymphocytes with sera from TB patients. However, following the injection of lymphocytes preincubated with sera from healthy volunteers, AI remained the same as after the injection of MNC preincubated with sera from healthy volunteers (1.06 $\pm$ 0.04 vs. 1.07 $\pm$ 0.06).

The IL-12p40 serum level was significantly elevated in TB patients (355 $\pm$ 279 pg/ml; $p < 0.01$) compared to that of healthy controls (64 $\pm$ 70 pg/ml) (Fig. 3a). A significant correlation was found between the IL-12p40 serum level and angiogenic properties of sera of the examined patients and healthy donors ($r = 0.57$, $p < 0.01$) (Fig. 4a). TNF-a serum level from TB patients (31 $\pm$ 8 pg/ml; $p < 0.002$) was significantly elevated compared to that of healthy controls (21 $\pm$ 3.4 pg/ml) (Fig. 3b). A significant
correlation \( r = 0.62, p < 0.01 \) between TNF\( \alpha \) serum level and angiogenic activity of sera was found (Fig. 4b).

**Discussion**

These results confirm suggestions [16, 17] of the involvement of angiogenesis in TB. The positive correlation between angiogenic activity measured by the number of newly created vessels after the injection of MNC preincubated with sera of TB patients and IL-12p40 and TNF\( \alpha \) serum concentration levels seems to suggest that these cytokines play an important role in the pathogenesis of the neovascularization [29, 30]. Our previous studies carried out on the same model did not confirm any correlation between angiogenic activity of sarcoidosis patients’ sera and IL-6 and IL-8 serum levels [10]. However, TNF\( \alpha \), an important proinflammatory factor, may stimulate angiogenesis in interstitial lung diseases, and a weak correlation was observed between the serum level of IL-12 and the...
Matsuyama et al. [18] reported higher VEGF levels in the sera of patients with active pulmonary TB. This indicates that VEGF is involved in the pathogenesis of pulmonary TB, which is supported by studies showing that the number of new vessels created after intradermal injection of MNC preincubated with sera from interstitial lung diseases patients [31, 32]. Our results support the hypothesis that the increased blood vessel formation and oxygen supply caused by the overexpression of VEGF inhibits cavity formation in TB. However, studies of Alatas et al. [17] did not confirm these findings. These authors observed a significant increase of VEGF serum level in active TB, and a correlation between angiogenic activity of sera from TB patients and IL-12 and TNFα. These cytokines, which play an important role in the pathogenesis of TB, also modulate angiogenesis [25, 26, 29, 30]. Significant correlations between the concentration of these cytokines and radiological findings in TB patients were found [24]. Some reports point to neovascularization in the pathogenesis of tuberculosis. Thus, Abe et al. [16] suggest that the increased blood vessel formation and oxygen supply caused by the overexpression of VEGF inhibits cavity formation in TB. However, studies of Alatas et al. [17] did not confirm these findings. These authors observed a significant increase of VEGF serum level in active TB, and a decrease with effective antituberculosis treatment [17]. Matsuyama et al. [18] reported higher VEGF levels in the sera of patients with active pulmonary TB. Mycobacterium tuberculosis-infected monocytes develop a matrix-degrading phenotype [33]. Matrix degradation is the essential first step in the process of creating new vessels from the preexisting vasculature. In TB meningitis, monocytes secrete matrix metalloproteinase-9, which facilitates leukocyte migration across the blood-brain barrier [34]. TNFα plays an important role in this process as well [35]. Lipoolarabinomannan, one of the main M tuberculosis antigens, stimulates macrophages to release metalloproteinase-9, which, by breaking down proteins, not only causes formation of cavities but also induces angiogenesis [35]. A correlation between VEGF and TNFα was also observed in the pathogenesis of exudate in tuberculous pleuritis [20]. TNFα is produced by various cells in the inflammatory site and induces angiogenic cytokines, including IL-8, VEGF, and basic fibroblast growth factor (bFGF), all of which are involved in neovascularization [36]. Saita et al. [37] demonstrated that intracorneal challenge with trehalose 6,6'-dimycolate derived from M tuberculosis induces an inflammatory response, including granuloma formation and neovascularization. The angiogenic reaction was inhibited by neutralizing antibodies targeting VEGF and IL-8, partially by anti-TNFα antibodies, but not by anti-IL-1β [37]. Macrophages stimulated with cord factor produce proinflammatory type-1 helper-T-cell-inducing cytokines, including TNFα, IL-1, chemotactic factors, and IL-12 [38]. In time it leads to the increase of VEGF concentration [38].

Establishing the key role of the monocytes in inducing angiogenic activity when affected by sera of TB patients is an important result of this study. The angiogenic effect of TB patients’ sera was different than that of sera from healthy donors. Healthy human sera stimulated stronger lymphocytes than monocytes. In the case of TB patients, depletion of monocytes from MNC decreased the proangiogenic effect of the sera; therefore, the proangiogenic factors present in the patients’ sera stimulated mainly monocytes and had no such strong effect on lymphocytes. From this observation we may conclude that the main proangiogenic effect of TB patients’ sera is mediated by macrophages/monocytes. Matsuyama et al. [18] showed by immunohistochemistry that the expression of VEGF occurred in the alveolar macrophages around active TB lesions. It has been demonstrated that VEGF plays a role in the pathogenesis of pulmonary M avium complex infection [39]. Therefore, it can be assumed that activated macrophages are the main cells that secrete VEGF in TB lesions when affected by factors such as IL-12 and TNFα. Pulmonary TB and sarcoidosis are granulomatous diseases and their pathogenesis has been linked to monocytes and alveolar macrophages [40, 41]. Meyer et al. [42] pointed out the key role of monocytes from sarcoidosis patients in stimulating neovascularization. In an earlier study we also demonstrated that sera from sarcoidosis patients prime monocytes for production of proangiogenic factors [10]. Sakaguchi et al. [43] indicated that trehalose 6,6'-dimycolate augments VEGF production by neutrophils and

---

**Fig. 4** a Correlation between angiogenic activity of sera from TB patients (n = 13) or from healthy controls (n = 10) and IL-12 serum level. b Correlation between angiogenic activity of sera from TB patients (n = 12) or from healthy controls (n = 9) and TNFα serum level (r = Pearson’s coefficient)
macrophages and induces neovascularization in granulomatous tissue. Chronic inflammation in TB is characterized by a localized accumulation of mononuclear cells, i.e., the formation of a granuloma that is surrounded by neovascularization [41]. Angiogenesis is required for the progression of chronic inflammation [3].

IL-12 is a multifunctional cytokine produced by macrophages and dendritic cells. As a factor promoting the commitment of naïve lymphocytes to a Th1-type profile of cytokine expression, IL-12 may be pivotal in the cascade of proinflammatory events in the lungs [44]. The number of cells expressing Th1-type cytokines such as INFγ and IL-12 is increased within the lungs of patients with granulomatous disease such as TB and sarcoidosis [29]. IL-12 not only stimulates the growth of T and NK cells but also inhibits angiogenesis in solid tumors [45]. IL-12 is a heterodimeric cytokine composed of p40 and p34 chains. The subunit of IL-12p40 is in a free form, which blocks specific receptors to stimulate angiogenesis; this determined the selection of this cytokine for this study. Heterodimeric IL-12 and free p40 were present in tuberculous pleural effusions but not in malignant pleural effusions, suggesting that IL-12 is produced in the local immune response to infection [46]. Cooper et al. [47] have demonstrated that IL-12p40 knockout mice are defective in their ability to induce INFγ production and to generate a protective Th1-type of immunologic response in TB. IL-12 proved to be an effective and successful adjuvant to a standard treatment in patients suffering from progressive clinical TB [48].

It is difficult to determine whether neovascularization plays a beneficial or a harmful role in the course of TB. It can only be assumed that the growth of a localized inflammatory mass requires neovascularization. Insufficient angiogenesis resulting in hypoxia creates favorable conditions for tissue necrosis and cavity formation. Therefore, further research on neovascularization and its role in the pathogenesis of TB is necessary.

Conclusions

Sera from TB patients constitute a source of mediators participating in angiogenesis. Sera from TB patients prime monocytes for production of proangiogenic factors, TNFα and IL-12p40 as important proinflammatory factors may stimulate angiogenesis in TB.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257
2. Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237–368
3. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457–465
4. Firestein GS (1999) Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103:3–4
5. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularisation by insulin-like growth factor-1 receptor. Nat Med 5:1390–1395
6. Rogers PA, Gargett CE (1998) Endometrial angiogenesis. Angiogenesis 2:287–294
7. Chandall DL, Hausman GL, Kral JG (1997) A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 4:211–232
8. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ (2004) Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 59:581–585
9. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM (2005) CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 171:261–268
10. Zielonka TM, Demkow U, Białas B, Filewska M, Zycinska K, Radzikowska E, Szopińska J, Skopinska-Rózsewska E (2007) Modulatory effect of sera from sarcoidosis patients on mononuclear cells-induced angiogenesis. J Physiol Pharmacol 58(Suppl 5): 753–766
11. Shibuya M (2001) Structure and function of VEGF/VEGF receptor system involved in angiogenesis. Cell Struct Funct 26:25–35
12. Keane MP, Strieter RM (2002) The importance of balanced proinflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res 3:5–11
13. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178–187
14. Mittermayer F, Pleiner J, Schaller G, Weltermann A, Kapiotis S, Jilma B, Wolzt M (2003) Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotoxin-induced acute inflammation in humans. Eur J Clin Invest 33: 758–761
15. Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y (2003) Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 181:259–265
16. Abe Y, Nakamura M, Oshika Y, Hatanaka H, Tokunaga T, Okubo Y, Hashizume T, Suzuki K, Fujino T (2001) Serum levels of vascular endothelial growth factor and cavity formation in active pulmonary tuberculosis. Respiration 68:496–500
17. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, Yildirim H (2004) Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 125:2156–2159
18. Matsuura M, Hashiguchi T, Matsumuro K, Iwami F, Hirotzu Y, Kawabata M, Arimura K, Osame M (2000) Increased serum levels of vascular endothelial growth factor in pulmonary tuberculosis. Am J Respir Crit Care Med 162:1120–1122
19. Kizopoulos TS, Kostikas K, Gourgoulianis KI (2005) Vascular endothelial growth factor levels in pleural fluid and serum of patients with tuberculous pleural effusions. Chest 128:468–469
20. Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A (2004) Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology 9:81–86
21. Matsuyama W, Hashiguchi T, Umehara F, Matsuura E, Kawabata M, Arimura K, Maruyama I, Osame M (2001) Expression of vascular endothelial growth factor in tuberculous meningitis. J Neurol Sci 186:75–79
22. Ramakrishnan S, Rajesh M, Sulochana KN (2007) Eales’ disease: oxidant stress and weak antioxidant defence. Indian J Ophthalmol 55:95–102
23. Ridley MJ, Heather CI, Brown I, Willoughby DA (1983) Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. J Pathol 141:97–112
24. Casarini M, Ameglio F, Alemanno L, Zangrilli P, Mattia P, Paone G, Bissetti A, Giose` S (1999) Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am J Respir Crit Care Med 159:143–148
25. Brion ChA, Gazzinelli RT (1995) Effect of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcomes. Curr Opin Immunol 7:485–496
26. Bergron A, Bonay M, Kambouchner M, Lecossier D, Riquet M, Soler P, Hance A, Tazi A (1997) Cytokine patterns in tuberculous and sarcoid granulomas. J Immunol 159:3034–3043
27. Sidky YA, Auerbach R (1975) Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-versus-host reaction. J Exp Med 140:1084–1100
28. Zielonka TM, Demkow U, Filewska M, Bialas B, Zycinska K, Wardyn KA, Skopinska-Rozewska E (2007) TNFalpha and INFgamma IL-6, IL-8, IL-12 and TNF-alpha gene polymorphisms in pulmonary tuberculosis. J Immunol 166:4223–4230
29. Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS (2001) Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 166:4223–4230
30. Chang JC, Wysocki A, Tchou-Wang KM, Moskowitz N, Zhang Y, Rom WN (1996) Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 51:306–311
31. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015–4023
32. Taha RA, Minshall EM, Olivenstein R, Ihaku D, Wallaert B, Benoit M, Arimura K, Maruyama I, Osame M (2001) Trehalose 6,6´-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 68:5991–5997
33. Sakaguchi I, Ikeda N, Kato Y, Yano I, Kaneda K (2000) Trehalose 6,6´-dimycolate (cord factor) induces angiogenesis and inflammatory reaction. J Exp Med 191:1049–1051
34. Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS (2001) Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 166:4223–4230
35. Chang JC, Wysocki A, Tchou-Wang KM, Moskowitz N, Zhang Y, Rom WN (1996) Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 51:306–311
36. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015–4023
37. Taha RA, Minshall EM, Olivenstein R, Ihaku D, Wallaert B, Benoit M, Arimura K, Maruyama I, Osame M (2001) Trehalose 6,6´-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 68:5991–5997
38. Oswald IP, Dozois CM, Petit JF, Lemaire R (1997) Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages. Infect Immun 65:1364–1369
39. Nishigaki Y, Fujisaki S, Fujita Y, Yamazaki Y, Sato M, Yamamoto Y, Takeda A, Fujikane T, Shimizu T, Kikuchi K (2006) Increased serum level of vascular endothelial growth factor in Mycobacterium avium complex infection. Respiratory 11:407–413
40. Müller-Quernheim J (1998) Sarcoidosis: immunopathogenic concepts and their clinical application. Eur Respir J 12:716–738
41. Kobayashi Y, Yoshida T (1996) The immunopathogenesis of granulomatous inflammation induced by Mycobacterium tuberculosis. Methods 9:204–214
42. Meyer KC, Kaminski MJ, Calhoun WJ, Auerbach R (1989) Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis. I. Enhanced capacity of bronchoalveolar lavage cells from patients with pulmonary sarcoidosis to induce angiogenesis in vivo. Am Rev Respir Dis 140:1446–1449
43. Sakaguchi I, Ikeda N, Nakayama M, Kato Y, Yano I, Kadena K (2000) Trehalose 6,6´-dimycolate (cord factor) enhances neovascularization through vascular endothelial growth factor production by neutrophils and macrophages. Infect Immun 68:2043–2052
44. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S (1993) Natural killer cell stimulatory factor (IL-12) induces Th helper type (Th1) specific immune responses and inhibits the development of IL-4 producing Th2 cells. J Exp Med 177:1199–1204
45. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S (2000) Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 60:1111–1116
46. Zhang M, Gately MK, Wang E, Gong J, Wolf SF, Lu S, Modlin RL, Barnes PF (1994) Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 93:1733–1739
47. Cooper AM, Magram J, Ferrante J, Orme IM (1997) Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 186:39–45
48. Greinert U, Ernst M, Schlaak M, Entzian P (2001) Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J 17:1049–1051